NGNE — Neurogene Inc
NASDAQ · Healthcare · Biotechnology
$37.87
+$1.63 (+4.50%)
Neurogene Inc (NGNE) is a biotechnology company listed on NASDAQ. It is led by Rachel L. McMinn Ph.D., based in 535 W 24th Street, New York, NY, United States, 10011, with about 107 employees. Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Latest reported NGNE revenue for 2025-09-30 was $0. Net income was -$21.0M. NGNE currently screens at market cap $286.5M.
Use this NGNE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NGNE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NGNE SEC filings page. Lician reads the product cache first so this HTML stays unique to Neurogene Inc even when a live quote feed is slow.
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
NGNE Key Statistics
Market Cap
$286.53M
Volume
180,073
Previous Close
$40.84
Day Range
$38.27 – $41.77
EPS
-$4.28
Revenue
$925.00K
Net Income
-$75.14M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-8123.7%
Employees
107
NGNE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $925.00K | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$75.14M | $13.65M | -$55.19M | -$60.69M |
| EPS (Diluted) | -$4.28 | $2.93 | -$1.04 | -$1.10 |
Total Assets
$335.73M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$136.59M
Operating Cash Flow
-$70.60M
Free Cash Flow
$0.00
Neurogene Inc Company Information
- Founder, Executive Chair & CEO
- Rachel L. McMinn Ph.D.
- Headquarters
- 535 W 24th Street, New York, NY, United States, 10011
- Website
- www.neurogene.com
- Phone
- 855 508 3568
- IPO / Founded
- 2014-03-07
- Sector
- Healthcare
- Industry
- Biotechnology